Malignant Peripheral Nerve Sheath Tumor
What's New
Last Posted: Apr 18, 2024
- NF1-Driven Rhabdomyosarcoma Phenotypes: A Comparative Clinical and Molecular Study of NF1-Mutant Rhabdomyosarcoma and NF1-Associated Malignant Triton Tumor.
Henry de Traux de Wardin, et al. JCO precision oncology 2024 0 e2300597 - Malignant Peripheral Nerve Sheath Tumor in a Patient With BAP1 Tumor Predisposition Syndrome.
Kaszuba Megan C, et al. World neurosurgery 2017 0 362-364 - Melanoma Mimicking Malignant Peripheral Nerve Sheath Tumor with Spread to the Cerebellopontine Angle: Utility of Next-Generation Sequencing in Diagnosis.
Fox Hanson Katie, et al. Case reports in pathology 2018 0 9410465 - Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
Pemov Alexander, et al. Neuro-oncology 2019 0 (8) 981-992 - Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor?Like Melanoma.
Muniz Thiago P, et al. The Journal of investigative dermatology 2021 0 (10) 2470-2479 - Impact of Transcript (p16/p14ARF) Alteration on Cancer Risk in CDKN2A Germline Pathogenic Variant Carriers.
Sargen Michael R, et al. JNCI cancer spectrum 2022 0 (6) - Malignant peripheral nerve sheath tumor in children: A clinicopathologic and molecular study with parallels to the adult counterpart.
Agaram Narasimhan P, et al. Genes, chromosomes & cancer 2022 0 (3) 131-138 - Genetic alterations associated with malignant transformation of sporadic vestibular schwannoma.
Håvik Aril Løge, et al. Acta neurochirurgica 2021 0 (2) 343-352 - The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.
Pemov A, et al. Oncogene 2017 0 (22) 3168-3177 - Prevalence and detection of actionable BRAF V600 and NRAS Q61 mutations in malignant peripheral nerve sheath tumor by droplet digital PCR.
Kao Erica Y, et al. Human pathology 2022 9 - CLINGEN Actionability Report for Neurofibromatosis type 1 - NF1
ClinGen Actionability Working Group - Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
Stewart Douglas R et al. Genetics in medicine : official journal of the American College of Medical Genetics 2018 Jul 20(7) 671-682 - Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53.
Høland Maren, et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018 6 - Frequent HRAS Mutations in Malignant Ectomesenchymoma: Overlapping Genetic Abnormalities With Embryonal Rhabdomyosarcoma.
Huang Shih-Chiang, et al. The American journal of surgical pathology 2016 2 - Probe-based quantitative PCR assay for detecting constitutional and somatic deletions in the NF1 gene: application to genetic testing and tumor analysis.
Terribas E, et al. Clinical chemistry 2013 2 - Malignant peripheral nerve sheath tumor
From NCATS Genetic and Rare Diseases Information Center
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Content source: